http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2009539970-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2007-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2009539970-A |
| titleOfInvention | How to treat cancer |
| abstract | Use of a macrolide antibiotic used in the manufacture of a medicament for the treatment or prevention of cancer selected from colorectal cancer, tendonoma, bladder cancer, gastric cancer, and breast cancer, wherein the antibiotic is tylosin, pharmacology Pharmaceutically acceptable salts and derivatives thereof; erythromycin, pharmaceutically acceptable salts and derivatives thereof; oleandomycin, pharmaceutically acceptable salts and derivatives thereof; and spiramycin, pharmaceutically acceptable One or more of its salts and derivatives thereof. The present invention also provides a pharmaceutical composition for treating or preventing the above cancer, a method for treating or preventing the above cancer, and a method for treating or preventing a cancer expressing a mutant APC gene in mammals. [Selection figure] None |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190130037-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020528047-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11077126-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102327332-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7060631-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020516609-A |
| priorityDate | 2006-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 181.